LOS ANGELES, CA / ACCESSWIRE / August 12, 2019 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Curaleaf Holdings, Inc. (“Curaleaf”or “the Company”) (OTCQX:CURLF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. The FDA sent a warning letter to Curaleaf on July 22, 2019. The FDA letter stated that the Company was selling several CBD products on its website that were “misbranded drugs,” a violation of the Federal Food, Drug, and Cosmetic Act. Based on this news, shares of Curaleaf fell more than 7% on July 23, 2019.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of charge. You can also reach us through the firm’s website at www.schallfirm.com, or by email at email@example.com.